Research advancement on EGFR mutation detection in peripheral blood of patients with non-small cell lung cancer / 肿瘤研究与临床

ABSTRACT

The main therapies of NSCLC are surgery, chemotherapy, radiotherapy and targeted therapy. With development of targeted therapy, it was found that tyrosine kinase inhibitor(TKI) for patients with mutations in the EGFR gene was effective. Screening of such drugs before treatment is a premise of individualized treatment, and tissue samples are the current gold standard for genetic testing. However, it is hard to acquire the tumor tissues of patients with advanced NSCLC, so EGFR mutations detection of free DNA in peripheral blood had become an option. This article reviews the detections of TKIs-sensitive mutation,exon 19/21 mutation, and TKIs-acquired resistant mutation, T790M mutation at exon20, in serum or plasma of NSCLC patients.